$BCRX Galidesivir (BCX4430, Immucillin-A) is an antiviral drug, an adenosine analog[1] (a type of nucleoside analog).[2] It is developed by BioCryst Pharmaceuticals with funding from NIAID, originally intended as a treatment for hepatitis C, but subsequently developed as a potential treatment for deadly filovirus infections such as Ebola virus disease, Marburg virus disease and Zika virus. Currently, Galidesivir is under phase 1 human trial in Brazil for Coronavirus.[3] --- WIKIPEDIA source ---- So "Why don't use Gali to help Japan Health Care system ? Yesterday on Pharma Japan ***** "Active Hep C Treatment Estimated to Save 1.3 Trillion Yen in Healthcare Costs in 20 Years: INES **** pj.jiho.jp/article/243255
  • 4
  • 2
4 Likes